Status:
COMPLETED
Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings
Lead Sponsor:
Pfizer
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Brief Summary
This prospective observational cohort study will assess the average duration of the drug free interval between etanercept treatment cycles in usual care settings in Germany.
Detailed Description
Non-interventional study: subjects to be selected according to the usual clinical practice of their physician
Eligibility Criteria
Inclusion
- Subjects with moderate to severe plaque psoriasis on etanercept treatment according to the Summary of Product Characteristics (SmPC), and applicable local guidelines
- Subjects for whom the decision has already been made to initiate treatment with etanercept
Exclusion
- Sepsis or risk of sepsis
- Current or recent infections, including chronic or localized, e.g. tuberculosis (TB) infection
- Vaccination with live vaccine in last 4 weeks, or expected to require such vaccination during the course of the study
- Pre-existing or recent onset CNS demyelinating disease.
- Class III or IV congestive heart failure as defined by the New York Heart Association classification or uncompensated congestive heart failure.
- Previous or ongoing treatment with etanercept
- Participation in other clinical or observational studies.
- Patients with psoriatic arthritis requiring continuous etanercept treatment.
Key Trial Info
Start Date :
June 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
926 Patients enrolled
Trial Details
Trial ID
NCT00708708
Start Date
June 1 2008
End Date
December 1 2013
Last Update
July 27 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Westfaelische Wilhelms-Universitaet Muenster, Zentr. f. Derm
Münster, North Rhine-Westphalia, Germany, 48149